CAR TCR Cell Therapy Patent Improves Cytokine Signaling
Summary
USPTO published patent application US20260098074A1 by inventors Ruth E. Winter and Saikat Banerjee for CAR and/or TCR cell therapy improving cytokine signaling. The patent covers methods for enhancing immune cell function through improved cytokine signaling pathways in cell therapy applications. The application was filed on 2025-07-15.
What changed
USPTO published patent application US20260098074A1 for a CAR and TCR cell therapy invention that improves cytokine signaling to enhance immune cell function. The patent covers cell therapy methods and compositions for improving immune cell performance through cytokine pathway modifications.\n\nCell therapy developers, biotechnology companies, and pharmaceutical manufacturers should review the patent claims to assess potential licensing needs, freedom-to-operate considerations, and competitive landscape implications for CAR-T and TCR-based therapies.
What to do next
- Monitor for patent issuance and claims examination updates
- Review patent claims for potential licensing or infringement implications
- Assess freedom to operate in cell therapy space
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
IMMUNE CELL FUNCTION
Application US20260098074A1 Kind: A1 Apr 09, 2026
Inventors
Ruth E. Winter, Saikat Banerjee
Abstract
The present disclosure relates to the field of cell therapy, and more specifically, to improving CAR and/or TCR function through improvement of improvement of cytokine signaling.
CPC Classifications
C07K 14/7051 A61K 40/11 A61K 40/31 A61K 40/4211 A61K 40/4261 C07K 14/70521 C07K 16/30 C12N 5/0636 A61K 2239/31 A61K 2239/38 A61K 2239/48 C07K 2317/622 C07K 2319/03 C07K 2319/33 C12N 2510/00
Filing Date
2025-07-15
Application No.
19269381
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.